Is Maxposure overvalued or undervalued?

As of 8 September 2025, the valuation grade for Maxposure has moved from very attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics, with a PE Ratio of 16.77, an EV to EBITDA of 11.32, and a ROCE of 26.06%.
In comparison to its peers, Maxposure's PE Ratio is lower than that of Prime Focus, which stands at 29.25, suggesting that while Maxposure is fairly valued, it may have room for improvement relative to more attractive peers. The recent stock performance shows that Maxposure has underperformed the Sensex over the past year, with a decline of 43.09% compared to a slight increase of 0.32% for the index, reinforcing the notion that the stock may be facing challenges in the current market environment.